Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Page Path

HOME
ARTICLE CATEGORY
Editorial

Editorial

Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?

Joo Hyun Oh, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(2):367-370. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0054 Correction in: Clin Mol Hepatol 2023;29(3):828

View: 2594 Download: 66 Web of Science: 3 Crossref: 2

The imitator of immune-tolerant chronic hepatitis B: A killer in disguise

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol. 2023;29(2):363-366. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0079

View: 2805 Download: 88 Web of Science: 1 Crossref: 1

The current trends in the health burden of primary liver cancer across the globe

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(2):358-362. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0092

View: 2983 Download: 64 Web of Science: 2 Crossref: 2

The latest global burden of liver cancer: A past and present threat

Joo Hyun Oh, Dae Won Jun

Clin Mol Hepatol. 2023;29(2):355-357. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0070

View: 3704 Download: 103 Web of Science: 17 Crossref: 22

Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan

San-Chi Chen

Clin Mol Hepatol. 2023;29(2):352-354. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0101

View: 2705 Download: 64

Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap

Shen-Yung Wang

Clin Mol Hepatol. 2023;29(2):349-351. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0082

View: 2612 Download: 62

The prime time for management of hepatocellular carcinoma in Hong Kong

Landon L. Chan, Stephen L. Chan

Clin Mol Hepatol. 2023;29(2):345-348. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0094

View: 2583 Download: 55

Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences

Tian Yang, Ming-Da Wang, Xin-Fei Xu, Chao Li, Han Wu, Feng Shen

Clin Mol Hepatol. 2023;29(2):342-344. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0106

View: 3004 Download: 65 Web of Science: 4 Crossref: 6

The clinical management of hepatocellular carcinoma in China: Progress and challenges

Shan Shan, Jidong Jia

Clin Mol Hepatol. 2023;29(2):339-341. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0077

View: 3112 Download: 99 Web of Science: 2 Crossref: 3

Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma

Do Young Kim

Clin Mol Hepatol. 2023;29(2):335-338. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0107

View: 2762 Download: 54

What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?

Min Kyung Park, Yoon Jun Kim

Clin Mol Hepatol. 2023;29(2):332-334. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0080

View: 2522 Download: 51 Crossref: 1

New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?

Young-Suk Lim

Clin Mol Hepatol. 2023;29(1):118-119. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0413

View: 3294 Download: 177 Web of Science: 2 Crossref: 2

Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers

Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2023;29(1):113-117. Published online October 31, 2022

DOI: https://doi.org/10.3350/cmh.2022.0333

View: 3097 Download: 99 Web of Science: 3 Crossref: 4

Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey

Susana G Rodrigues

Clin Mol Hepatol. 2023;29(1):110-112. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0414

View: 3542 Download: 101 Web of Science: 2 Crossref: 2

Non-invasive tests-based risk stratification: Baveno VII and beyond

Georg Semmler, Mathias Jachs, Mattias Mandorfer

Clin Mol Hepatol. 2023;29(1):105-109. Published online November 23, 2022

DOI: https://doi.org/10.3350/cmh.2022.0361

View: 3954 Download: 134 Web of Science: 6 Crossref: 7

The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus

Jeong-Ju Yoo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(1):102-104. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0353

View: 3346 Download: 146 Web of Science: 1 Crossref: 1

The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(1):99-101. Published online October 27, 2022

DOI: https://doi.org/10.3350/cmh.2022.0321

View: 3330 Download: 86 Web of Science: 3 Crossref: 3

Surveillance for hepatocellular carcinoma: It is time to move forward

Bo Hyun Kim, Yuri Cho, Joong-Won Park

Clin Mol Hepatol. 2022;28(4):810-813. Published online September 6, 2022

DOI: https://doi.org/10.3350/cmh.2022.0257

View: 3060 Download: 91 Web of Science: 5 Crossref: 5

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):806-809. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0208

View: 2539 Download: 68

Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations

Soon Sun Kim, Jae Youn Cheong

Clin Mol Hepatol. 2022;28(4):802-805. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0249

View: 2725 Download: 75 Web of Science: 2 Crossref: 3

Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults

Byoung Seok Ye

Clin Mol Hepatol. 2022;28(3):481-482. Published online May 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0097

View: 2875 Download: 75 Web of Science: 1 Crossref: 2

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease

Seonghwan Hwang, Won Kim

Clin Mol Hepatol. 2022;28(3):478-480. Published online June 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0143

View: 3203 Download: 91

Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?

Qian Jin, Rui-Xu Yang, Jian-Gao Fan

Clin Mol Hepatol. 2022;28(3):473-477. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0155

View: 3645 Download: 99 Web of Science: 2 Crossref: 2

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles

Hung-Yao Lin, Tai-Chung Tseng

Clin Mol Hepatol. 2022;28(2):181-182. Published online February 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0028

View: 4242 Download: 118 Web of Science: 3 Crossref: 3

Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis

Takumi Kawaguchi, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):177-180. Published online August 26, 2021

DOI: https://doi.org/10.3350/cmh.2021.0246

View: 4807 Download: 178 Web of Science: 3 Crossref: 2

Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still open

Bo Hyun Kim

Clin Mol Hepatol. 2022;28(2):174-176. Published online January 26, 2022

DOI: https://doi.org/10.3350/cmh.2021.0400

View: 3785 Download: 110 Web of Science: 3 Crossref: 3

Non-alcoholic fatty liver disease in pregnancy, paving the way for adverse pregnancy outcome risk assessment

Ja-Young Kwon

Clin Mol Hepatol. 2022;28(1):50-51. Published online November 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0359

View: 3951 Download: 97

Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?

Seung Mi Lee, Won Kim

Clin Mol Hepatol. 2022;28(1):47-49. Published online November 30, 2021

DOI: https://doi.org/10.3350/cmh.2021.0338

View: 4118 Download: 110 Web of Science: 4 Crossref: 4

Can hepatocellular carcinoma recurrence be prevented after liver transplantation?

Jong Man Kim

Clin Mol Hepatol. 2021;27(4):562-563. Published online September 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0276

View: 3905 Download: 130 Web of Science: 2 Crossref: 2

Microwave thermosphere versus radiofrequency ablation for hepatocellular carcinoma: Are we approaching the time to end the debate?

Man-Deuk Kim

Clin Mol Hepatol. 2021;27(4):560-561. Published online September 8, 2021

DOI: https://doi.org/10.3350/cmh.2021.0279

View: 3722 Download: 123 Web of Science: 1 Crossref: 1

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

14.0
First decision

09 Days

Publication after acceptance

03 Days

*Last 12 months

MOST VIEWED MOST CITED

MOST VIEWED (Last 6 months)

Viewed By 5504	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5404	MAFLD: How is it different from NAFLD?
Viewed By 5214	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5094	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4725	Global incidence and prevalence of nonalcoholic fatty liver disease

MOST CITED (2022-2024)

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: kasl@kams.or.kr

Copyright © The Korean Association for the Study of the Liver.

COUNTER

TODAY : 195

TOTAL : 1931298